“In common with other estrogens, transdermal estradiol inhibits bone resorption, as evidenced by reduction in urinary excretion of calcium and hydroxyproline and other metabolic markers of bone resorption, and small increases in bone mineral density (BMD) in postmenopausal women receiving long term treatment.”